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The axon/dendrite speciﬁcation collapsin response mediator protein-2 (CRMP-2) bidirectionally
regulates N-type voltage-gated Ca2+ channels (CaV2.2). But how cyclin dependent kinase 5 (Cdk5)-
mediated phosphorylation of CRMP-2 affects its interaction/regulation with CaV2.2 is unknown.
CRMP-2-mediated enhancement of currents via CaV2.2 was not observed with a Cdk5 phospho-null
CRMP-2-S522A mutant or in cells expressing an inactive Cdk5. Concomitant knockdown of endog-
enous CRMP2 and overexpression of CRMP2-S522A mutant refractory to knockdown phenocopied
the reduction in Ca2+ inﬂux while the Rho kinase CRMP2-T555A mutant was ineffective. Cdk5-
phosphorylated CRMP-2 had increased association with CaV2.2. These results identify an important
role for Cdk5 in CRMP2-mediated CaV2.2 regulation.
Structured summary of protein interactions:
Gsk3b phosphorylates Crmp2by phosphatase assay (View interaction)
Crmp2 physically interacts with Cav2.2 by anti tag coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Recent studies by our laboratory have identiﬁed CRMP-2 as aCollapsin response mediator protein-2 (CRMP-2) speciﬁes axon/
dendrite fate and axonal growth of neurons. Initially identiﬁed in
chick sensory neurons as a protein responsible for growth cone
retraction in response to negative guidance signals in the semaph-
orin 3A (Sema3A) pathway [1], CRMP-2 analogues were subse-
quently identiﬁed in Caenorhabditis elegans (uncoordinated
protein-33 (Unc-33)) [2], in rodents ((named turned on after devel-
opment 64 (TOAD-64)) in rats and Unc-33 like phosphoprotein
(Ulip) in mice) [3–5], in humans (HUlip) [6,7] and in Drosophila
Melanogaster [8]. Together with its established roles in neurite
growth and retraction and kinesin-dependent axonal transport,
mapping the CRMP-2 interactome has revealed previously unap-
preciated functions including affecting microtubule dynamics, pro-
tein endocytosis and vesicle recycling, as well as synaptic assembly
(see reviews by Hensley [9] and Strittmatter [10]).chemical Societies. Published by E
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, United States. Fax: +1 (317)modulator of synaptic transmission through interactions with the
presynaptic N-type voltage-gated Ca2+ channel (CaV2.2) [11–13].
Inﬂux of calcium via CaV2.2 is critical for transmitter release with-
in many synapses [14–16]. In 2009, we reported the existence of a
biochemical complex between CRMP-2 and CaV2.2 in hippocampal
/cortical neurons [11]; the interaction was enhanced in an activity-
dependent fashion implying dynamic regulation [11]. Extensive
reciprocal mapping revealed the binding to two regions within
CaV2.2 and a short sequence within CRMP-2 [11,17]. The latter
region, referred to as Ca2+ channel binding domain 3 (CBD3), was
sufﬁcient to mediate the interaction as a synthetic peptide derived
from this region could abrogate binding between the proteins [17].
Consistent with the interaction being the basis of the reported
CRMP-2-mediated enhancement of CaV2.2 [11,12], the CBD3
peptide was able to reduce channel surface expression and Ca2+
current. A cell penetrant version of the CBD3 peptide acutely
inhibited synaptic transmission in hippocampal slices further
suggesting a dynamic regulation of CaV2.2 by CRMP-2 [17]. Impor-
tantly, systemic administration of the cell permeable CBD3 peptide
exhibited remarkable efﬁcacy in attenuating tactile hyperalgesia in
several models of neuropathic pain with no off-target effects
[17–19], consistent with previous reports wherein genetic or phar-
macological ablation of CaV2.2 led to similar reductions in tactile
hyperalgesia [20,21]. Collectively, these ﬁndings have established
CRMP-2 as an important regulator of CaV2.2 function.lsevier B.V. All rights reserved.
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CaV2.2, it is unknown under what circumstances this interaction
can be dynamically modiﬁed. Precedence for this is exempliﬁed
in CRMP-2’s interaction with tubulin; phosphorylation of CRMP-2
by cyclin dependent kinase 5 (Cdk5), glycogen synthase kinase 3
beta (GSK-3b) and/or Rho-dependent kinase (RhoK) lowers the
ability of CRMP-2 to interact with tubulin which leads to arrest
of axonal growth and collapse of cones [22–24]. Phosphorylation,
by glycogen synthase kinase-3b (GSK-3b), cyclin dependent kinase
5 (Cdk5), and Rho kinase [10], as well as calmodulin dependent
protein kinase II (CaMKII) [25] and the src family kinase Fyn [26]
and Yes [27] have been reported, identifying phosphorylation as
a fulcrum in CRMP-2 signaling. Based upon the established impor-
tant role of phosphorylation in modulating CRMP-2’s activity and
interaction with partners proteins, we hypothesized that phos-
phorylation may also affect its modulation of CaV2.2. Here, we fo-
cused solely on evaluating the effect of Cdk5-phosphoryalted
CRMP-2 on CaV2.2 because (i) Cdk5 is an obligatory priming kinase
[28], (ii) Cdk5-phosphorylated CRMP-2 (at Ser-522) has reduced
interaction with partner proteins tubulin and numb [24], (iii)
Cdk5-phosphorylated CRMP-2 leads to altered neuronal function-
ality manifested as a halt in neurite growth [29], and (iv) the
Cdk5-phosphorylation site is near the CBD3 binding site on
CRMP-2 that is important for its interaction with CaV2.2. Our re-
sults show that mutation of the Cdk5-phosphorylation site, but
not the RhoK phosphorylation site, regulates CRMP-2-mediated
enhancement of Ca2+ inﬂux. Phosphorylation of CRMP-2 by Cdk5
also increases the interaction between CaV2.2 and CRMP-2. Thus,
phosphorylation of CRMP-2 by Cdk5 is a dynamic regulator of
CaV2.2 function.2. Materials and methods
2.1. Isolation and culture of hippocampal or cortical neurons
Rat hippocampal and cortical neuron cultures were prepared
from hippocampi or cortices dissected from postnatal day 2
(PN2) or embryonic day 19 (E19) rats, respectively, exactly as de-
scribed [11].
2.2. Generation of CRMP-2 DsRed and CRMP-2 mutants
Mouse CRMP-2 cDNA (Mus musculus accession # NM_009955.3)
was cloned into pDsRed2-N1 using PCR ampliﬁcation followed by
restriction digest and ligation. All mutations were made as previ-
ously described using Quikchange II XL (Agilent Technologies, San-
ta Clara, CA) and veriﬁed by DNA sequencing [30]. Constructs for
wildtype and dominant negative CdK5 were purchased from Add-
gene (Cambridge, MA).
2.3. Transfection of cortical/hippocampal neurons
Adherent hippocampal cultures were transfected with cDNAs
using Lipofectamine 2000 (Invitrogen) as previously described
[11], transfected at 10 days in vitro (DIV) and used for experiments
2–3 days later.
2.4. Electrophysiology
Whole cell Ca2+ currents were recorded from PN2 hippocampal
neurons grown for 12–13 DIV, then transfected and tested 2–
3 days later, as described previously [11]. Whole-cell calcium cur-
rents were isolated using the following solutions: external (bath)
medium (in mM): NaCl 128, KCl 5, MgCl2 1, BaCl2 10, D-glucose
10, HEPES-Na 10, and tetraethylammonium-Cl 10; with an osmo-larity of 300 mosm/l and pH 7.3; patch electrode intracellular solu-
tion: CsCl2 110, EGTA 10, MgSO4 1, HEPES(Cs) 25, ATP 2, and GTP
0.2; osmolarity 305 mosm/l, pH 7.4. Tetrodotoxin (1 lM; Alomone
Laboratories) was added in the bath solution to block Na+ and L-
type Ca2+ channels. All recording solutions contained the L-type
Ca2+ channel antagonist Nifedipine (10 lM) to isolated CaV2.2 cur-
rent; at this stage in culture and under these conditions, the major-
ity of Ca2+ currents are due to CaV2.2 [11].
2.5. Culturing Catecholamine A Differentiated (CAD) cells
The neuronally derived CAD cells were grown at 37 C and in 5%
CO2 as previously described [30,31]. CAD cells were transfected as
described above.
2.6. Knockdown of CRMP-2 expression by siRNA
A siRNA against the CRMP-2 target sequence 50-[GTAAACTC
CTTCCTCGTGT]-30 was used to knockdown endogenous CRMP-2
as described previously [11]. A scramble siRNA with matching G/
C content was used as control.
2.7. Treatment of cortical neurons with kinase Inhibitors
PN2 hippocampal neurons grown for 9 DIV were treated with
either vehicle (0.1% methyl-2-pyrrolidone; MPL), 10 lM Purvalanol
A, or 10 lMY27632. Purvalanol A is a Cdk5 speciﬁc inhibitor where
a concentration of 10 lM has been previously shown to reduce
phosphorylation of CRMP-2 in culture [32]. Y27632, a RhoK speciﬁc
inhibitor (IC50 0.7 lM), was used at 10 lM to ensure maximal
inhibition [33]. Neurons were treated for 1, 2, or 18 h with the
drugs before being washed in cold phosphate buffer saline (PBS),
then harvested by homogenization in a modiﬁed RIPA buffer
(50 mM Tris–HCl, pH 8, 1% NP-40, 150 mM NaCl, 0.5% Na deoxy-
cholate, and 1 mM EDTA with protease inhibitors). Lysates were
subsequently immunoblotted for total CRMP-2 (Sigma, St. Louis,
MO) and CRMP-2 phosphorylated at Ser-522 (ECM Biosciences,
Versailles, KY).
2.8. In vitro phosphorylation of CRMP-2 by Cdk5
CRMP-2-6xHis, a kind gift from Dr. Rihe Liu (University of North
Carolina) was phosphorylated in vitro as previously described with
minor modiﬁcations [28]. Puriﬁed Cdk5-GST (1 lM) and its cofac-
tor, p25-GST (10 lM) were incubated at room temperature for 2 h
to activate the kinase. CRMP-2-His was then incubated in Kinase
assay buffer (100 mM HEPES pH 7.2, 20 mM MgCl2, 2 mM MgATP,
2 mM DTT) along with 200 nM activated Cdk5/p25 and/or 200 nM
GSK-3b for 1 h at 30 C. Samples were then boiled in Laemmli sam-
ple buffer prior to being analyzed by immunoblotting.
2.9. Fura-2AM Ca2+imaging of transfected cortical neurons
Fura-2AM (Invitrogen, Carlsbad, CA) Ca2+ imaging was per-
formed on E19 cortical neurons as described [47]. At 7–8 DIV, cells
were co-transfected with pDsRed-CRMP-2 KDR constructs (WT,
S522A, S522D, T555A, T555E) and/or 200 nM CRMP-2 siRNA using
Lipofectamine 2000 (Invitrogen). Cells were then imaged 2–3 days
following transfection.
2.10. Co-immunoprecipitation and immunoblotting
Synaptosomes from PN2 rat brains were isolated as described
[11]. Rat brain lysates were generated by homogenization and gen-
tle sonication in a detergent free modiﬁed RIPA buffer (50 mM
Tris–HCl, pH 8, 150 mM NaCl, and 1 mM EDTA with protease
J.M. Brittain et al. / FEBS Letters 586 (2012) 3813–3818 3815inhibitors). Lysates were incubated with CRMP-2-6xHis, following
phosphorylation, and immunoprecipitated (IP) with a 6xHis anti-
body (UC Davis/NIH NeuroMab Facility, clone N144/14) overnight
at 4 C with gentle rotation. Samples were then incubated with
Protein G-agarose for 2 h at 4 C before being processed by immu-
noblotting for CaV2.2 (Origene, Rockville, MD). Blots were digitized
and quantiﬁed using Un-Scan-It gel version 6.1 scanning software
(Silk Scientiﬁc Inc., Orem, UT) as described previously [11].
3. Results
We ﬁrst veriﬁed that Cdk5 was active in our PN2 hippocampal
neuron cultures by treating neurons with the Cdk5 inhibitor pur-
valanol A (10 lM). As a negative control, neurons were also treated
with the RhoK inhibitor Y-27632 (10 lM), which does not affect
phosphorylation of CRMP-2 at Ser-522. A time-dependent decrease
in phosphorylation of CRMP-2 at Ser-522 was detected using a Ser-
522 phospho-speciﬁc antibody (Fig. 1A, B). Predictably, treatment
with Y-27632 did not change the relative amount of Ser-522A
phosphorylated CRMP-2 (Fig. 1A, B). These pilot experiments dem-Wi
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Fig. 1. Cdk5-mediated phosphorylation of CRMP-2 regulates CaV2.2. (A) Lysates
from neurons exposed to Cdk5 inhibitor Purvalanol, the Rho Kinase inhibitor Y-
27632, or vehicle (0.1% DMSO) for the indicated times were immunoblotted with
the indicated antibodies. (B) Summary data of ratio CRMP-2 p522 to total CRMP-2
and then normalized to vehicle-treated neurons (n = 5–6 from two separate
experiments, ⁄P < 0.05, one-way ANOVA with Dunnett’s post-hoc compared to
vehicle). (C) Peak Ca2+ current density (pA/pF), measured at +10 mV from a holding
potential of 80 mV, of PN2 hippocampal neurons grown for 10–12 DIV and
transfected with the various constructs as indicated (n = 7–12; ⁄P < 0.05 one-way
ANOVA compared to EGFP-expressing cells).onstrated that our neuronal cultures had sufﬁcient functional Cdk5
supporting their use in investigating the role that Cdk5-mediated
phosphorylation of CRMP-2 plays in its interaction and regulation
of CaV2.2. Because pharmacological inhibition of Cdk5 may affect
diverse cellular pathways, we chose a more direct genetic ap-
proach wherein we transfected neurons with CRMP-2 mutants that
were incapable of being phosphorylated by Cdk5 (S522A) or mim-
icked constitutive phosphorylation (S522D) and measured Ca2+
currents using whole-cell voltage clamp electrophysiology. Over-
expression of wildtype CRMP-2 led to twofold increase in Ca2+
currents (Fig. 1C), consistent with our previous reports [11,17]. In
contrast, overexpression of CRMP-2 S522A or S522D constructs
did not increase currents above levels in neurons transfected with
a control (EGFP) construct (Fig. 1C), suggesting that Cdk5-phos-
phorylation, and potentially dephosphorylation, of CRMP-2 is re-
quired for its regulation of CaV2.2. That expression of a wildtype
Cdk5 increased, while a Cdk5 dominant negative (DN) dead kinase
decreased, Ca2+ currents (Fig. 1C) further supports this conclusion.
That the S522D phospho-mimetic mutation had the same effect
as the S522A phospho-null mutation suggested the possibility that
the lack of a potential effect on Ca2+ currents may be due to the
presence of endogenous CRMP-2 which could compete and sup-
plant the effects, if any, of the phosphorylation mutants. To cir-
cumvent this, we generated a CRMP-2 construct resistant to
knockdown to (KDR) by siRNA by introducing silent mutations of
three nucleotides within the siRNA target sequence without alter-
ation of the amino acid sequence (Fig. 2A). Immunoblot analysis for
CRMP-2 demonstrated that levels of the CRMP-2-KDR protein were
not different between CAD and a neuronal cell line and cells trans-
fected with CRMP-2 or scramble siRNAs (Fig. 2B). The CRMP-2 siR-
NA very effectively reduces levels of CRMP-2 in CAD cells
compared with cells transfected with scramble siRNA (Fig. 2B).
Next, we generated the S522D phospho-mimetic and S522A phos-
pho-null mutations into this CRMP-2 KDR contruct. Additional
constructs with mutations at T555, the RhoK phosphorylation site,
were created as controls. All four constructs, the two phospho-mi-
metic mutants (S522D and T555E) and phospho-null mutants
(S522A and T555A) exhibited robust protein expression similar
to overexpressed wildtype (WT) CRMP-2, suggesting that the
mutations did not alter expression of the CRMP-2 protein (Fig. 2C).95
kDa
Sc
ram
ble
 
CR
MP
-2
Sc
ram
ble
 
CR
MP
-2
WT KDR
siRNA:
CRMP-2
β−Tubulin  72
 95
kDa  W
T
 S5
22
A
 S5
22
D
 T5
55
A
 T5
55
E
CRMP-2-DsRed
CRMP-2 
A
CB
GGG|GTA|AAC|TCC|TTC|CTC|GTG|TAC
 G      V      N      S      F       L      V      YSequence
CRMP-2 wildtype (WT)
CRMP-2 knockdown resistant (KDR)
siRNA target sequence
701 725
GGG|GTA|AAT|AGC|TTC|CTC|GTG|TAC
KDR 
52
Fig. 2. Generation of knockdown resistant CRMP-2 and expression of CRMP-2
mutants. (A) Alignment of the protein (top) and nucleotide sequences (bottom)
within a validated siRNA region targeting CRMP-2 highlighting the silent mutations
(underlined nucleotides) that were introduced to generate DNA that would be
knockdown resistant (KDR). Numbers refer to nucleotides from the mouse CRMP-2
sequence (GenBank Accession # NM_009955.3). (B) Lysates from CAD neuronal
cells co-transfected with wildtype (WT) CRMP-2-Dsred and scramble or CRMP-2
siRNAs or KDR CRMP-2-Dsred and scramble or CRMP-2 siRNAs were probed with
CRMP-2 (top) or a loading control (b-tubulin, bottom). CRMP-2-KDR is refractory to
knockdown compared to WT CRMP-2. (C) Phospho-mimetic or -null mutations
engineered into the CRMP-2-KDR-DsRed construct express robustly.
75
52
kDa
p25/Cdk5+ +
+ +
CRMP-2 (Total)
A
B
Ly
sa
te
Rx
n b
uff
er
Cd
k5
Cd
k5
 + 
GS
K3
β
GS
K3
β
IP: 6x-His
CRMP-2
CaV2.2
CRMP-2-6xHis +    +    +    +
260
CRMP-2 p522
Amido black stain
70
70
kDa
C 2.0
1.0
0.0N
or
m
al
iz
ed
 
C
aV
2.
2 
bo
un
d
Rx
n b
uff
er
Cd
k5
Cd
k5
 + 
GS
K3
β
GS
K3
β
*
CRMP-2 p522
GSK3β
Fig. 4. Phosphorylation of CRMP-2 enhances its interaction with CaV2.2. (A)
Puriﬁed CRMP-2-6xHis was phosphorylated in vitro by incubation with Cdk5/p25
and/or GSK-3b. Phosphorylation of CRMP-2 by Cdk5 at Ser-522 was monitored by
immunoblotting as indicated. (B) Cdk5-phosphorylated CRMP-2-6xHis was incu-
bated with E19 cortical neuron lysates and then immunoprecipitated (IP) for
CaV2.2–CRMP-2 protein complexes with an anti-6xHis antibody before immuno-
blotting for CaV2.2 and CRMP-2 p522. The amido black stain demonstrates equal
amounts of protein across all lanes. The increases in CaV2.2 recovered by CdK5 +
GSK3b- or GSK3b-phosphorylated CRMP-2, compared to without added Cdk5, were
atypically greater than the average. (C) Summary of mean ± SEM CaV2.2 bound to
CRMP-2 (n = 5). Data are normalized to the amount of CaV2.2 bound to CRMP-2 in
the absence of exogenously added kinases (i.e. Rxn buffer). Asterisk denotes
signiﬁcance difference compared to Rxn buffer (P < 0.05, Student’s t-test).
3816 J.M. Brittain et al. / FEBS Letters 586 (2012) 3813–3818Next, we tested if the KDR phospho-mutant constructs could
affect Ca2+ inﬂux. Cortical neurons grown for 7–8 DIV were co-
transfected with KDR phospho-mutant constructs and CRMP-2
siRNA (200 nM), and depolarization-evoked Ca2+-inﬂux was
monitored with the Ca2+-sensitive dye Fura-2AM two days later.
Transfected cells were visualized using the red ﬂuorescent protein
DsRed, which was fused to the CRMP-2 KDR constructs. Stimula-
tion with 46.5 mM KCl led a rapid increase in the Fura-2AM ratio
which is indicative of an increase in intracellular calcium concen-
tration ([Ca2+]i) (Fig. 3A). Depolarization-evoked inﬂux of Ca2+
was greater in neurons expressing wildtype CRMP-2 KDR com-
pared to cells expressing S522A-CRMP-2-KDR (Fig. 3A, B). Analysis
of the peak ﬂuorescence ratios was used to compare between the
various CRMP-2-KDR constructs. Following knockdown of endoge-
nous CRMP-2, we observed that depolarization-evoked Ca2+ inﬂux
was signiﬁcantly lower in neurons transfected with either CRMP-2
Cdk5 phospho-mimetic or phospho-null mutants compared to
neurons transfected with wildtype CRMP-2 (P < 0.05, Student’s
t-test; Fig. 3B). Depolarization-evoked Ca2+ inﬂux in neurons
expressing T555 RhoK site phospho-mimetic or phospho-null
mutants of CRMP-2 was not different from wildtype CRMP-2
expressing neurons (P > 0.05, Student’s t-test; Fig. 3B). These
results suggest that regulation of CRMP-2’s interaction with
CaV2.2 is speciﬁc to Ser-522 phosphorylation as mutation to the
Thr-555 sites elicited no change in Ca2+-inﬂux.
As we have previously demonstrated that CRMP-2 exists in a
biochemical complex with CaV2.2 [11,17], we next sought to
determine if the phosphorylation of CRMP-2 could regulate this
interaction. Bacterially produced recombinant histidine-tagged
CRMP-2 (CRMP-2-6xHis) was phosphorylated in vitro by Cdk5
and its cofactor p25 (the subunit p25 is necessary for Cdk5 kinase
activity [34]), by GSK-3b alone, or by Cdk5/p25 + GSK-3b and phos-
phorylation was monitored by immunoblotting with an anti-
CRMP-2 p522 antibody (Fig. 4A). The in vitro phosphorylated
CRMP-2 was then used to enrich for the CaV2.2 complex from P2
rat brain synaptosomes. The complexes were recovered by
immunoprecipitation with a monoclonal antibody against 6xHis,
resolved by SDS poly acrylamide gel electrophoresis and immuno-
blotted for CaV2.2, total and phosphorylated CRMP-2. Both Cdk5/
p25- and Cdk5/p25/GSK-3b-phosphorylated CRMP-2 precipitated
CaV2.2 much more than unphosphorylated CRMP-2 (Fig. 4B, top
blot). Cdk5/p25-phosphorylated CRMP-2 led to an 52% increase
in binding to CaV2.2 compared to samples without exogenous0 2 4
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our results from Fura-2AM Ca2+-imaging and whole-cell voltage
clamp electrophysiology Ca2+ current and support the notion that
phosphorylation of Ser-522 is an important determinant of
CRMP-2’s modulation of CaV2.2 function.4. Discussion
In addition to its canonical roles in neurite outgrowth, the web
of interactions characterized now for CRMP-2 with motor proteins,
kinases, channels, receptors, enzymes, and endocytosis–exocytosis
related proteins suggests that CRMP-2 may serve as adaptors/
scaffold molecules and as trafﬁc ‘cops’ [9]. Our laboratory has
championed CRMP-2 as an important determinant of synaptic
transmission [11–13,17,18]. Our ﬁndings demonstrate that Cdk5-
phosphorylation of CRMP-2 enhances the interaction between
CRMP-2 and CaV2.2 while reducing axon growth [28].
As it was recently demonstrated that Cdk5 signals through the
adaptor protein Ca2+/calmodulin-dependent serine protein kinase
(CASK) to regulate trafﬁcking of CaV2.2 [35], we utilized Cdk5
phospho-mimetic and -null mutants of CRMP-2 to speciﬁcally
investigate the role that phosphorylation of CRMP-2 by Cdk5 has
on the CRMP-2–CaV2.2 interaction. Mutation of Ser-522 to either
an alanine or an aspartic acid prevented the CRMP-2-mediated
augmentation of Ca2+ inﬂux as conﬁrmed by the dual approaches
of electrophysiology in hippocampal neurons and Ca2+ imaging in
cortical neurons. Interestingly, Ca2+ inﬂux using mutations of the
RhoK phosphorylation site (Thr-555) CRMP-2 was no different
from wildtype CRMP-2, implying that RhoK does not regulate this
interaction. In contrast, phosphorylation of CRMP-2 by either RhoK
or Cdk5 leads to growth cone collapse [23,36] as well as disrupts
interactions of CRMP-2 with both tubulin and numb [24]. Thus,
phosphorylation of CRMP-2 by different kinases may allow ﬁne
tuning of only a subset of CRMP-2 interactions and functions and
driving only particular signaling cascades. In support of this asser-
tion is the ﬁnding that Cdk5-phosphorylation of CASK likely frees it
to interact with presynaptic proteins including CaV2.2 [35]. As
Cdk5-mediated phosphorylation of CASK increased Ca2+ currents
via CaV2.2, it is possible that Cdk5 affects CaV2.2 indirectly by
modulating CRMP-2 phosphorylation and thus CaV2.2 activity. A
recent paper from the Tsai group demonstrated that CaV2.2 itself
is a Cdk5 substrate and phosphorylation by this kinase increases
neurotransmitter release [37]. These ﬁndings may also explain
why we saw a greater augmentation of Ca2+ current in Cdk5-over-
expressing neurons compared to those expressing CRMP-2 as well
an enhanced degree of interaction between the two proteins. An-
other possibility is that given the proximity of the CBD3 sequence
in CRMP-2 to the Cdk5 consensus site in CRMP-2, it is likely that
phosphorylation of CRMP-2 leads to a conformational shift culmi-
nating in an increased likelihood of the CBD3 sequence to bind
CaV2.2. In summary, we have identiﬁed two roles for Cdk5-phos-
phorylated CRMP-2: regulating Ca2+ inﬂux via CaV2.2 and increas-
ing the interaction with CaV2.2.
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